The purpose of this article is to review physiologic insulin replacement using a basal-prandial approach and focus on the role of postprandial glucose control. In addition, therapeutic options for optimizing glycemic control are described, including diabetes education, currently available agents, treatment regimens, and strategies.
Methods
This article reviews the benefits of treating with a basal-prandial insulin approach and focuses on post prandial glucose-targeted therapies, including rapid- acting insulin analogs.
Results
Data from landmark clinical trials in type 2 diabetes suggest that intensive glycemic control can reduce the frequency and severity of diabetes complications. A basal-prandial insulin regimen combines a long-acting insulin analog with a rapid-acting insulin to mimic normal physiologic insulin secretion, providing a flexible tool to enhance patient self-management.
Conclusions
Strategies that include patient education, improved health care provider/patient communication, and basal-prandial insulin treatment can help patients achieve good glycemic control. The optimal setting for successful diabetes treatment is a team approach with the health care provider, nurse/certified diabetes educator, and patient as essential members.
Get full access to this article
View all access options for this article.
References
1.
Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States. Available at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2003.pdf. Accessed September 14, 2005.
2.
DeWitt DE, Dugdale DC. Using new insulin strategies in the outpatient treatment of diabetes: clinical applications. JAMA. 2003;289:2265-2269.
3.
DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA. 2003,289: 2254-2264.
4.
Funnell MM, Kruger DF, Spencer M. Self-management support for insulin therapy in type 2 diabetes. Diabetes Educ. 2004,30: 274-280.
5.
Wallace TM, Matthews DR. Poor glycaemic control in type 2 diabetes: a conspiracy of disease, suboptimal therapy and attitude. QJM. 2000,93:369-374.
6.
Salgo P, moderator. Paradigm shifts in diabetes management. 2003. Available at: 2005.
7.
Parkin CG, Brooks N. Is Postprandial Glucose Control Important? Is It Practical In Primary Care Settings?Clinical Diabetes. 2002, 20:71-76.
8.
Del Prato S, Marchetti P, Bonadonna RC. Phasic insulin release and metabolic regulation in type 2 diabetes. Diabetes. 2002, 51(suppl 1):S109-S116.
9.
American Diabetes Association. Postprandial blood glucose. Diabetes Care. 2001,24:775-778.
10.
White JR Jr, Campbell RK, Hirsch IB. Novel insulins and strict glycemic control: analogues approximate normal insulin secretory response. Postgrad Med [serial online]. 2003;113-113. Available at: www.postgradmed.com/issue/2003/06_03/1white.htm. Accessed October 11, 2004.
11.
Mitrakou A, Kelley D, Veneman T, et al. Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes. 1990,39:1381-1390.
12.
Bonora E, Calcaterra F, Lombardi S, et al. Plasma glucose levels throughout the day and HbA(1c) interrelationships in type 2 diabetes: implications for treatment and monitoring of metabolic control. Diabetes Care. 2001;24:2023-2029.
13.
Kelley D. Approaches to preventing prandial hyperglycemic excursions. Endocrinol Diabetes. 1999,6:S7-S11.
14.
Palumbo PJ. Gycemic control, mealtime glucose excursions, and diabetic complications in type 2 diabetes mellitus. Mayo Clin Proc. 2001;76:609-618.
15.
Mayfield JA, White RD. Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function. Am Fam Physician. 2004;70:489-500.
16.
Carroll MF, Gutierrez A, Castro M, Tsewang D, Schade DS. Targeting postprandial hyperglycemia: a comparative study of insulinotropic agents in type 2 diabetes. J Clin Endocrinol Metab. 2003,88:5248-5254.
17.
Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care. 1997;20:1822-1826.
18.
Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care. 1997,20:1822-1826.
19.
Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. Lancet. 1999;354:617-621.
20.
Feinglos MN, Thacker CH, English J, Bethel MA, Lane JD. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes. Diabetes Care. 1997;20:1539-1542.
21.
Donahue RP, Abbott RD, Reed DM, Yano K. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes. 1987;36:689-692.
22.
Bonora E. Postprandial peaks as a risk factor for cardiovascular disease: epidemiological perspectives. Int J Clin Pract Suppl. 2002;129:5-11.
23.
Bastyr E Jr, Stuart CA, Brodows RG, et al. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group. Diabetes Care. 2000;23:1236-1241.
24.
Dimitriadis GD, Gerich JE. Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus. Diabetes Care. 1983,6:374-377.
25.
Mudaliar SR, Mohideen P, Baxi SC, et al. Pharmacodynamic and pharmacokinetic properties of a premixed 85/15 human insulin preparation. Clin Ther. 2001;23:404-412.
26.
Heller S. Reducing hypoglycaemia with insulin analogues. Int J Obes Relat Metab Disord. 2002,26(suppl 3):S31-S36.
27.
Hollander P. Premixed insulins: how do they compare with other insulin preparations?Postgrad Med. 1991;89:52-61.
28.
Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care. 2000;23:644-649.
29.
Hershon KS, Blevins TC. Once-daily insulin glargine compared with twice-daily NPH insulin in patients with type 1 diabetes. Endocr Pract. 2004;10:10-17.
30.
Rosenstock J, Park G, Zimmerman J. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. US Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Diabetes Care. 2000;23: 1137-1142.
31.
Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care. 2001;24:631-636.
Anderson JH Jr, Brunelle RL, Keohane P, et al. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. Arch Intern Med. 1997;157:1249-1255.
38.
Gale EA. A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with type 1 diabetes on intensified insulin therapy. The UK Trial Group. Diabet Med. 2000;17:209-214.
39.
Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care. 2000;23:583-588.
40.
Dailey G, Rosenstock J, Moses RG, Ways K. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care. 2004;27:2363-2368.
41.
Dreyer M, Prager R, Robinson A, Busch K, Souhami E. Efficacy and safety of insulin glulisine (GLU) and insulin lispro (IL), combined with insulin glargine (GLAR) in patients with type 1 diabetes. Diabetes. 2004;53:A123-A123.
42.
Nosek L, Becker RHA, Frick AD, Kapitza C, Heise T, Rave K. Prandial blood glucose control with pre and post-meal insulin glulisine versus regular human insulin. Diabetes. 2004;53:A139-A140.
43.
Garg S, Rosenstock J, Ways K. Insulin dose and weight profiles of pre and post-meal insulin glulisine (GLU) in a basal-bolus regimen with insulin glargine in patients with type 1 diabetes. Diabetes. 2004;53:A125-A126.
44.
Woolf SH, Davidson MB, Greenfield S, et al. Controlling blood glucose levels in patients with type 2 diabetes mellitus: an evidence-based policy statement by the American Academy of Family Physicians and American Diabetes Association. J Fam Pract.2000;49:453-460.
Overmann H, Heinemann L. Injection-meal interval: recommendations of diabetologists and how patients handle it. Diabetes Res Clin Pract. 1999;43:137-142.
48.
Heinemann L. Do insulin-treated diabetic patients use an injection-meal-interval in daily life?Diabet Med. 1995;12: 449-450.
49.
Hedman CA, Lindstrom T, Arnqvist HJ. Direct comparison of insulin lispro and aspart shows small differences in plasma insulin profiles after subcutaneous injection in type 1 diabetes. Diabetes Care. 2001;24:1120-1121.
50.
Home PD, Lindholm A, Hylleberg B, Round P. Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group. Diabetes Care. 1998;21: 1904-1909.
51.
Herbst KL, Hirsch IB. Insulin strategies for primary care providers. Clin Diabetes.2002;20:11-17.
52.
Chantelau E, Schiffers T, Schutze J, Hansen B. Effect of patient selected intensive insulin therapy on quality of life. Patient Educ Couns. 1997;30:167-173.
